Tirzepatide
Also known as: Tirzepatide (GIP/GLP-1 dual receptor agonist — Mounjaro, Zepbound)
Tirzepatide is a unimolecular dual GIP and GLP-1 receptor agonist with a half-life of approximately 5 days, enabling once-weekly subcutaneous dosing. It is FDA-approved as Mounjaro for type 2 diabetes (2022), Zepbound for chronic weight management in adults with obesity or overweight with a weight-related comorbidity (2023), and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (2024). It carries a BOXED WARNING for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Pricing for Tirzepatide
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for Tirzepatide
239 third-party tests across 38 vendors. Each card links to the full report.
For
Tirzepatide
by EZ Peptides· batch EZP-2P2005162026-04
For
Tirzepatide
by NG Peptide· batch TRZ20-13
For
Tirzepatide
by NG Peptide· batch TRZ30-12
For
Tirzepatide
by Ion Peptide· batch ION2T60-05042026
For
Tirzepatide
by Skye Peptides· batch TZ26-60-003
For
Tirzepatide
by Prime Peptides· batch 3112026TR
For
Tirzepatide
by Prime Peptides· batch 3082026TR
For
Tirzepatide
by Prime Peptides· batch 3122026TR
For
Tirzepatide
by Reta Peptide· batch 20260409
For
Tirzepatide
by OROS Research· batch OR-LPGLPT10-426-B3
For
Tirzepatide
by OROS Research· batch OR-LPGLPT5-426-B2
For
Tirzepatide
by SSR· batch 2026
For
Tirzepatide
by Peptidegurus· batch cmojgr3mz00239grxsn1virxc
For
Tirzepatide
by Hkuppeptide· batch 2026
For
Tirzepatide
by Peptiatlas· batch 2026
For
Tirzepatide
by Taikangbio· batch 2026
For
Tirzepatide
by Taishijie· batch 2026
For
Tirzepatide
by Vicopeptide· batch 2026
For
Tirzepatide
by Zjpeptix· batch 2026
For
Tirzepatide
by Peptidegurus· batch cmojgr3hz00229grxkvgluyy3
For
Tirzepatide
by Qihang Peptide· batch 4
For
Tirzepatide
by Qihang Peptide· batch 4
For
Tirzepatide
by Simple Peptide· batch GT60-0482026-1
For
Tirzepatide
by Skye Peptides· batch TZ26-30-002
36 citations indexed for Tirzepatide
cohort · 2026
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials
Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk.
Study · 2026
Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial
Background Initiation of treatment with tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GLP-1RA), early after a diagnosis of type 2 diabetes (T2D) may establish better and more durable glycemic control than current treatment approaches per guidelines…
Study · 2026
Real-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospective Observational Study
Introduction Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist, significantly affects glucose and body weight-lowering effects in randomized controlled trials. However, real-world clinical evidence in Japan remains limited.
animal · 2026
Tirzepatide and Intermittent Cold Exposure Independently Improve Glucose Homeostasis in DIO Mice Housed at Thermoneutrality
Obesity is considered a risk factor for metabolic diseases, including type 2 diabetes, and results from an imbalance between energy intake and energy expenditure.
Study · 2026
Cost-effectiveness and budget-impact analysis of tirzepatide in heart failure with preserved ejection fraction and obesity in the German health-care system
Background Heart failure with preserved ejection fraction is common, obesity-related, and associated with high symptom burden and healthcare use. Tirzepatide, a dual GIP/GLP-1 receptor agonist, improved symptoms and outcomes in SUMMIT, but its acquisition cost raises concerns about value and affordability.
Study · 2026
Impact of Tirzepatide Therapy on Thyroid Disease: Understanding Risks and Emerging Insights
The dual GLP-1/GIP agonist tirzepatide is a highly effective anti-obesity therapy. While promising, it is associated with potential adverse effects, including thyroid disease reported in animal models.